Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast for rhabdomyolysis in poisoned inpatients
IRCT20210720051946N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of montelukast in rhabdomyolysis (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Rate of decline of rhabdomyolysis and Creatine phosphokinase change. Started May 2022; status: completed.
02
Drugs
montelukast
03
Conditions
rhabdomyolysis
Beyond the preview
Go deeper on IRCT20210720051946N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210720051946N2.